## Impaired germinal center confinement and plasma cell differentiation by MYC activation is critical for Burkitt lymphomagenesis

Arief Gunawan, Amparo Toboso-Navasa, Stuart Horswell, Probir Chakravarty, Andrew Clear, Maria Calaminici and <u>Dinis Pedro Calado</u>

The Francis Crick Institute, Immunity and Cancer Laboratory, <a href="mailto:dinis.calado@crick.ac.uk">dinis.calado@crick.ac.uk</a>

## **Abstract**

Interference with plasma cell (PC) differentiation is considered a hallmark of activated B-cell (ABC) diffuse large B-cell lymphoma (DLBCL), in contrast to other germinal center (GC) B-cell lymphomas. ABC-DLBCLs have enforced NF- $\kappa$ B activity, which normally triggers B-to-PC differentiation. However, this is prevented by *BLIMP1*-loss or by enforced BCL6 expression, which represses *BLIMP1*.

Here, we hypothesized that interference with PC differentiation is an unappreciated general hallmark of GC-derived lymphomagenesis. The prototypical GC-derived Burkitt Lymphoma (BL) is devoid of NF- $\kappa$ B activity but displays increased Pl3K signaling; primarily thought to enhance cancer cell survival. However, like NF- $\kappa$ B, Pl3K can trigger B-to-PC differentiation. BLs also display MYC overexpression, increasing cell proliferation, and BCL6 expression as part of the GC program. It is unknown if BCL6 suffices to curb a Pl3K-driven PC differentiation pressure or instead MYC is required.

MYC forms with MIZ1 a transcriptional repressor complex in GC B-cells at the positive selection stage, where B-to-PC differentiation is initiated. We also found that MYC and MIZ1 are ubiquitously expressed in primary BLs. We generated mice overexpressing PI3K in GC B-cells together with MYC or a MYC mutant (vd) that cannot interact with MIZ1. Compared to MYCvd, MYC restricted pre-PC/PC formation, impaired GC confinement and exacerbated B-cell dissemination in blood; phenotypes reminiscent of BL mutations impairing S1PR2 signaling. Single cell RNAseq revealed differential enrichment for B-cell receptor signaling, acting cytoskeleton and Rho pathways; known regulators of PC differentiation and cell motility. In the long-term, MYCwt synergized with PI3K for BL development, whereas MYC<sub>VD</sub> developed PC hyperplasia, and was unable to form BL.

Thus, an unappreciated PI3K-driven PC differentiation pressure exists and MYC-MIZ1 complexes counteract this effect, ensuring BL development. Knowledge on the regulation and targets of MYC-MIZ1 complexes may uncover truly novel therapeutic opportunities for BL and other GC B-cell lymphomas.